| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| RAPT Therapeutics, Inc. | Director | Stock Option (right to buy) | 36.5K | $277K | $7.58 | May 23, 2024 | Direct |
| NGM BIOPHARMACEUTICALS INC | Director | Common Stock | 0 | $0 | $1.34 | Apr 5, 2024 | Direct |
| NGM BIOPHARMACEUTICALS INC | Director | Common Stock | 0 | $0 | $1.34 | Apr 5, 2024 | Indirect |
| Lyell Immunopharma, Inc. | Director | Option (right to buy) | 130K | May 15, 2025 | Direct | ||
| Lyell Immunopharma, Inc. | Director | Option (right to buy) | 130K | Jun 14, 2024 | Direct | ||
| NGM BIOPHARMACEUTICALS INC | Director | Stock Option (Right to Buy) | 0 | Apr 5, 2024 | Direct |